GUEST-EDITORS:

Giulia Treccani, University of Marburg, Germany

Todd Gould, University of Maryland School of Medicine, USA

In recent years, the field of psychopharmacology has witnessed rapid developments, with the potential to fundamentally transform the landscape of treatment options for neuropsychiatric disorders. Among the most notable advancements are for example the emergence of a rapid-acting antidepressant, ketamine, offering new hope that this finding will lead to further discovery and development of new possibilities for patients with depression.

Acta Neuropsvchiatrica announces a call for submissions to a special issue titled "Progress in Psychopharmacology," dedicated to showcasing the latest advancements in the field. This issue aims to cover a wide range of topics from preclinical science to cutting-edge overviews of new drugs in clinical trials to comprehensive pharmacoepidemiological studies, underscoring their significance in the treatment of neuropsychiatric disorders.

We invite researchers to contribute original articles and review papers that provide fundamental insights into both clinical and preclinical studies with a particular emphasis on novel findings in drug mechanisms of action, development, and treatment outcomes.

Final submissions are due February 1st 2025 on the journal submission site here.

Express interest in the issue here.

All submissions will be peer-reviewed.